Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChunrui LiBFBaijun FangLYLingzhi Yan

Discussion

Loading...

Member takes

Overview

Phase 2 study shows promising efficacy of aponermin-carfilzomib-dexamethasone in RRMM, indicating manageable adverse events.

Key Points

  • The overall response rate achieved was 70% in patients with relapsed/refractory multiple myeloma treated with novel regimens.
  • Progression-free survival was estimated at 11.4 months, indicating a potential clinical benefit for this patient population.
  • This prospective multi-center study evaluated the safety and efficacy of aponermin combined with carfilzomib and dexamethasone.
  • Findings suggest the aponermin-based regimens may be particularly effective for patients with complex treatment histories.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df46https://doi.org/10.1182/blood-2025-2271
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study2025
  2. 2Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma2025
  3. 3Phase 2 study of aponermin +kt-decp in patients(pts) with Relapsed/Refractory multiple myeloma and extramedullary disease2025
  4. 4Aponermin-based regimen as bridging therapy prior to CAR-T cell therapy for relapsed/refractory multiple myeloma2025
  5. 5Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma2025